Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Cyclophosphamide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Cyclophosphamide as a study intervention. Browse Cyclophosphamide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2804
Shown on this page
12
Current sort
Recently updated
Therapy scope
Cyclophosphamide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Cyclophosphamide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 457–468 of 2,804 matching trials for Cyclophosphamide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 2Phase 3 Interventional

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889
View directory record Official record
Conditions
Myasthenia Gravis, Generalized Myasthenia Gravis
Interventions
Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
Drug · Biological
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

NCT01025089
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
8
States / cities
Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

NCT04160390
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm
Interventions
Biospecimen Collection-Blood, Biospecimen Collection-Stool
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Recruiting Phase 1 Interventional

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

NCT06347068
View directory record Official record
Conditions
Breast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer
Interventions
iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Active, not recruiting Phase 1 Interventional

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

NCT03531736
View directory record Official record
Conditions
Myeloid Diseases
Interventions
Antithymocyte globulin (Rabbit), fludarabine, total body irradiation, cyclophosphamide, Rituxan, Allogeneic Hematopoietic Stem Cell Transplantation
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Middletown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

NCT00379340
View directory record Official record
Conditions
Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
199
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplant for Crohn's Disease

NCT03219359
View directory record Official record
Conditions
Crohn Disease
Interventions
Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab
Procedure · Drug
Lead sponsor
Aaron Etra
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Completed Phase 2 Interventional Results available

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

NCT02876302
View directory record Official record
Conditions
Inflammatory Breast Cancer (IBC)
Interventions
Ruxolitinib, Paclitaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Completed Phase 2 Interventional

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

NCT06588491
View directory record Official record
Conditions
Stiff-Person Syndrome, SPS
Interventions
Standard lymphodepletion regimen
Biological
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Completed Phase 2 Interventional Results available

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

NCT03712878
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil
Radiation · Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 31, 2026, 12:56 PM EDT
Recruiting Phase 2 Interventional

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

NCT07616154
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide 50mg, Abatacept, Alemtuzumab, Hydroxyurea, Thiotepa, Filgrastim, Sirolimus, Azathioprine, TBI, Hematopoietic Progenitor Cell Infusion
Drug · Radiation · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 31, 2026, 12:56 PM EDT

About this Cyclophosphamide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Cyclophosphamide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cyclophosphamide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Cyclophosphamide.